[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656147":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":26,"overallOfficials":13,"centralContacts":32,"locations":38,"responsibleParty":55,"collaborators":57,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":13,"studyType":77,"phases":78,"briefSummary":79,"conditions":80,"keywords":13,"overallStatus":41,"whyStopped":13,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Aneurysm Complete Occlusion Rate","Proportion of patients with complete occlusion of the target aneurysm at 1 year post-procedure, as assessed by the core imaging laboratory using the Raymond-Roy Occlusion Classification (Class I: complete obliteration).","1 year post-procedure",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":23,"description":13,"interventionNames":24},"Flow Diverter Stent Treatment Group","EXPERIMENTAL",[25],"Device: Novel Flow Diverter Stent",[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":13},"DEVICE","Novel Flow Diverter Stent","Patients with intracranial wide-neck aneurysms undergo implantation of new generation flow diverter stents (e.g., Pipeline Shield, Lattice, etc.) per IFU and local practice. Stent reconstructs parent artery, diverts flow, promoting aneurysm thrombosis. Concomitant antiplatelet therapy (DAPT: aspirin + clopidogrel\u002Fticagrelor) given per guidelines, continued ≥3-6 months post-procedure. This is a prospective, multicenter, single-arm, real-world study in China (≈15 sites, N=280). Follow-up: 30d, 6m, 1y, then annually to 4y post-procedure, including clinical (mRS) and imaging (DSA\u002FCTA) assessments.",[22],[33],{"name":34,"role":35,"phone":36,"phoneExt":13,"email":37},"Hengwei Jin","CONTACT","15001189679","jinhengwei123@163.com",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Beijing Tiantan Hospital, Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100070","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54],{"name":34,"role":35,"phone":36,"phoneExt":13,"email":37},{"type":56,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR",[58,60,62],{"name":59,"class":6},"Huashan Hospital",{"name":61,"class":6},"Peking University International Hospital",{"name":63,"class":6},"Beijing Chao Yang Hospital","100656147","a-multicenter-prospective-study-of-new-flow-diverter-stent-on-the-treatment-of-intracranial-aneurysms-in-china-100656147",false,"NCT07821957","A Multicenter Prospective Study of New Flow Diverter Stent on the Treatment of Intracranial Aneurysms in China","APRESENT","Inclusion Criteria:\n\n* Signed informed consent form and agreement to comply with protocol requirements.\n\nAge 22 to 80 years.\n\nDiagnosed with intracranial wide-neck aneurysm and planned for treatment with a flow diverter stent.\n\nParent artery distal\u002Fproximal diameter compatible with available sizes and models of flow diverter stents, and treatment to be performed in accordance with the China NMPA-approved indications and instructions for use.\n\nExclusion Criteria:\n\n* Need for treatment of another aneurysm in the affected territory of the target aneurysm using a different therapeutic modality during the study period.\n\nPrior intracranial implant (e.g., coils) in the target intracranial aneurysm territory within 6 months before enrollment.\n\nPrior surgery, including endovascular treatment, within 30 days before enrollment.\n\nModified Rankin Scale (mRS) score ≥ 3.\n\nAny known contraindication to flow diverter stent treatment or antiplatelet therapy, including contraindications to dual antiplatelet therapy (DAPT).\n\nPre-existing stent\u002Fflow diverter placed in the parent artery of the target aneurysm location.\n\nInvestigator judges that the patient's health or the validity of study results (e.g., high risk of neurological events, conditions that may increase the chance of stroke) could be compromised by study participation.\n\nWomen who are pregnant, breastfeeding, or planning to become pregnant during the study period.\n\nKnown allergy to platinum or cobalt-chromium alloys (including major elements: platinum, cobalt, chromium, nickel, or molybdenum).","ALL","22 Years","80 Years",{"count":75,"type":76},280,"ESTIMATED","INTERVENTIONAL",[15],"Intracranial aneurysm, as a common cerebrovascular disease, has a variety of treatment methods, including surgical treatment and endovascular treatment. Among these treatment methods, flow diverters have attracted much attention due to their unique therapeutic principles. Flow diverters help promote thrombus formation within the aneurysm by altering the direction and dynamics of blood flow, thereby achieving the purpose of treatment. 1-5 Flow diverters such as the Pipeline™ device have been proven to be safe and effective for the treatment of intracranial aneurysms and have gradually been recognized as the preferred device for the management of intracranial aneurysms.",[81],"Intracranial Aneurysm","2026-09-10",{"date":84,"type":85},"2026-09-16","ACTUAL",{"date":87,"type":85},"2026-01-06",{"date":89,"type":76},"2030-12-31",{"name":5,"class":6},1]